As part of our latest mini-series focusing on multiple myeloma, yesterday we looked at the BMS approach to tackling multiple myeloma with a variety of different modalities against BCMA and other targets.
Today it’s the turn of J&J’s Janssen to be in the BSB hot seat.
In the first part of the company interview today, we take a look at their current and strategic directions in CAR-T cell therapies, including some thought leader reactions. In the second part tomorrow morning we discuss what they are doing with their T cell engagers against different targets in multiple myeloma.
To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to the multiple myeloma landscape, subscribers can log-in or you can click to gain access to BSB Premium Content.
Salt Lake City, Utah – The CAR T cell therapy niche has certainly provided plenty of controversy, highlights and lowlights over the last decade or so, although much of the mainstream attention has really only surfaced in the last couple of years.
For those interested in this space, there is a short synopsis of the BMT Tandem 2018 plenary session that took place this weekend and simultaneously published in the ASBMT journal (See: Perales et al., 2018):
“Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR”
While no one doubts that we have a need for safer CARs to reduce or ameliorate severe toxicities (the debate here is what are the best ways to achieve that in the clinic), it remains unclear whether a fast or slow approach is the optimal way forward in terms of efficacy.
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space through the lens of several different academic institutions…
To learn more from thought leaders and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Dr Stephan Grupp at SITC17
National Harbor, MD – SITC 2017 wouldn’t be the same without an in-interview with Dr Stephan Grupp (CHOP) on the issues surrounding the Juno ROCKET trial and CAR T cell therapy safety.
This data has been eagerly awaited and anticipated by the field since the news of a cluster of lethal cerebral oedemas hit Juno in the summer 2016, seemingly out of the blue.
Yesterday, we reviewed the salient points from Dr Mark Gilbert (CMO) presentation highlighting their findings from the in-depth analyses performed to date.
In the second part we turn to a CAR T cell therapist with experience in treating children and young adults for his perspectives and candid reactions to the information presented.
We also talk about where the field is headed and some of the new developments we can look forward to hearing more about in the near to medium term future.
To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.